Pfizer/Organon Antipsychotic Deal: Positive Thoughts On Negative Symptoms
Executive Summary
Pfizer is paying $100 mil. up front for a second chance at the antipsychotic market through a licensing deal with Akzo Nobel's pharmaceutical division Organon
You may also be interested in...
Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan
Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20
Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan
Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20
Schering Gets CNS As Second Therapeutic “Corner” Via Organon Acquisition
Schering-Plough's planned acquisition of Organon would provide Schering with the entrée into the central nervous system marketplace it has been seeking